Amgen(US:AMGN) Ge Long Hui A P P·2026-02-04 02:35Core Viewpoint - Amgen reported a strong performance in Q4, with revenue and net profit significantly exceeding analyst expectations, indicating robust growth and operational efficiency [1] Financial Performance - Revenue for Q4 increased by 9% year-over-year to $9.87 billion, surpassing the average analyst estimate of $9.47 billion [1] - Net profit surged over 112% year-over-year to $1.33 billion, with adjusted earnings per share (EPS) at $5.29, exceeding the analyst forecast of $4.73 [1] - Product sales grew by 7%, driven by a 10% increase in product volume, although this growth was partially offset by a 4% decline in prices [1] Future Outlook - For the current year, Amgen projects revenue between $37 billion and $38.4 billion, with adjusted EPS expected to be between $21.6 and $23, compared to analyst expectations of $37.19 billion and $20.63 [1] - The company is conducting six Phase III trials for its experimental drug MariTide, targeting obesity and related conditions, including heart disease and sleep apnea [1] - Amgen plans to initiate a Phase III clinical study for MariTide in patients with type 2 diabetes this year [1]